EICHORCondition: Dry Eye Disease · Sponsor: Aramis Biosciences, Inc.
The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Aramis Site 113 | Birmingham, Alabama, United States | — |
| Aramis Site 121 | Garden Grove, California, United States | — |
| Aramis Site 120 | Glendale, California, United States | — |
| Aramis Site 106 | Long Beach, California, United States | — |
| Aramis Site 124 | Los Angeles, California, United States | — |
| Aramis Site 107 | Murrieta, California, United States | — |
| Aramis Site 102 | Newport Beach, California, United States | — |
| Aramis Site 116 | Petaluma, California, United States | — |
| Aramis Site 109 | Rancho Cordova, California, United States | — |
| Aramis Site 101 | Delray Beach, Florida, United States | — |
| Aramis Site 112 | Jacksonville, Florida, United States | — |
| Aramis Site 117 | Largo, Florida, United States | — |
+ 12 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05238597